Martin N Rossor

List of Publications by Citations

511 papers	62,610 citations	103 h-index	245 g-index
613 ext. papers	71,631 ext. citations	8.9 avg, IF	6.83 L-index

#	Paper	IF	Citations
511	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers and Dementia*, **2011**, 7, 263-9	1.2	8211
510	Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*, **1991**, 349, 704-6	50.4	3768
509	Current concepts in mild cognitive impairment. *Archives of Neurology*, **2001**, 58, 1985-92		3473
508	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurology, The*, **2007**, 6, 734-46	24.1	3067
507	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*, **2011**, 134, 2456-77	11.2	2970
506	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine*, **2012**, 367, 795-804	59.2	2272
505	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1088-93	36.3	2018
504	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
503	Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. *Nature*, **1991**, 353, 844-6	50.4	1082
502	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
501	Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. *Brain*, **2004**, 127, 701-12	11.2	877
500	Analysis of shared heritability in common disorders of the brain. *Science*, **2018**, 360,	33.3	666
499	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nature Genetics*, **2005**, 37, 806-8	36.3	648
498	Neuropeptide Y distribution in human brain. *Nature*, **1983**, 306, 584-6	50.4	613
497	11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurology, The*, **2010**, 9, 363-72	24.1	589
496	Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. *Lancet, The*, **1999**, 353, 183-9	40	586
495	A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. *Archives of Neurology*, **2003**, 60, 989-94		585

494	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. *Annals of Neurology*, **2001**, 49, 433-442	9.4	561
493	Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4703-7	11.5	511
492	The effects of donepezil in Alzheimer's disease - results from a multinational trial. *Dementia and Geriatric Cognitive Disorders*, **1999**, 10, 237-44	2.6	433
491	Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. *Neuroscience Letters*, **1980**, 20, 373-7	3.3	422
490	The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. *Nature Genetics*, **1995**, 11, 219-22	36.3	404
489	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. *Neurobiology of Disease*, **2008**, 32, 412-9	7.5	395
488	Posterior cortical atrophy. *Lancet Neurology, The*, **2012**, 11, 170-8	24.1	383
487	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nature Medicine*, **2019**, 25, 277-283	50.5	375
486	Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. *Lancet, The*, **2001**, 358, 201-5	40	371
485	Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. *Nature*, **1990**, 347, 194-7	50.4	371
484	Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. *NeuroImage*, **2002**, 17, 29-46	7.9	360
483	Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. *Human Molecular Genetics*, **1994**, 3, 569-74	5.6	344
482	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. *Brain*, **2012**, 135, 736-50	11.2	340
481	The diagnosis of young-onset dementia. *Lancet Neurology, The*, **2010**, 9, 793-806	24.1	340
480	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurology, The*, **2015**, 14, 253-62	24.1	328
479	Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. *Archives of Neurology*, **2000**, 57, 339-44		309
478	Visualisation and quantification of rates of atrophy in Alzheimer's disease. *Lancet, The*, **1996**, 348, 94-7	40	299
477	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS ONE*, **2010**, 5, e13950	3.7	276

476	Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. *Brain Research*, **1980**, 199, 147-60	3.7	273
475	Consensus classification of posterior cortical atrophy. *Alzheimer's and Dementia*, **2017**, 13, 870-884	1.2	261
474	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4502-9	11.5	253
473	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. *Brain*, **2011**, 134, 2565-81	11.2	251
472	Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. *Lancet Neurology, The*, **2006**, 5, 828-34	24.1	251
471	A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. *Nature Genetics*, **1992**, 2, 340-2	36.3	246
470	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science Translational Medicine*, **2014**, 6, 226ra30	17.5	244
469	Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. *American Journal of Human Genetics*, **2013**, 92, 345-53	11	242
468	Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. *Neuroscience Letters*, **1983**, 39, 95-100	3.3	242
467	A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. *NeuroReport*, **1995**, 7, 297-301	1.7	240
466	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurology, The*, **2018**, 17, 241-250	24.1	224
465	The clinical profile of right temporal lobe atrophy. *Brain*, **2009**, 132, 1287-98	11.2	220
464	Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. *Neuroscience Letters*, **1995**, 186, 17-20	3.3	220
463	Prion dementia without characteristic pathology. *Lancet, The*, **1990**, 336, 7-9	40	213
462	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
461	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. *Acta Neuropathologica*, **2010**, 120, 33-41	14.3	198
460	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. *Brain*, **2008**, 131, 706-20	11.2	198
459	Research priorities to reduce the global burden of dementia by 2025. *Lancet Neurology, The*, **2016**, 15, 1285-1294	24.1	197

458	EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. *European Journal of Neurology*, **2012**, 19, 1159-79	6	191
457	The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes. *Neuroscience Letters*, **1982**, 28, 217-22	3.3	189
456	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. *Lancet Neurology, The*, **2009**, 8, 334-44	24.1	187
455	Progressive logopenic/phonological aphasia: erosion of the language network. *NeuroImage*, **2010**, 49, 984-93	7.9	181
454	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. *NeuroImage*, **2010**, 53, 1070-6	7.9	181
453	Clinical review. Frontotemporal dementia. *BMJ, The*, **2013**, 347, f4827	5.9	172
452	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. *Lancet, The*, **2003**, 362, 1121-2	40	168
451	Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. *British Medical Bulletin*, **1986**, 42, 70-4	5.4	166
450	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2015**, 14, 291-301	24.1	165
449	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2016**, 3, 623-36	5.3	163
448	Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. *Annals of Neurology*, **2006**, 60, 145-7	9.4	163
447	Neurofilament inclusion body disease: a new proteinopathy?. *Brain*, **2003**, 126, 2291-303	11.2	162
446	Molecular nexopathies: a new paradigm of neurodegenerative disease. *Trends in Neurosciences*, **2013**, 36, 561-9	13.3	160
445	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. *Neurology*, **2017**, 89, 2167-2175	6.5	154
444	Familial non-specific dementia maps to chromosome 3. *Human Molecular Genetics*, **1995**, 4, 1625-8	5.6	153
443	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. *Brain*, **2013**, 136, 1399-414	11.2	148
442	In vivo detection of microglial activation in frontotemporal dementia. *Annals of Neurology*, **2004**, 56, 894-7	9.4	145
441	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. *Clinical Investigation*, **2012**, 2, 975-984		144

440	Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. *Neuroscience Letters*, **1999**, 259, 133-5	3.3	142
439	Assessing the onset of structural change in familial Alzheimer's disease. *Annals of Neurology*, **2003**, 53, 181-8	9.4	140
438	Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 1466-76	5.6	138
437	Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. *NeuroReport*, **1996**, 7, 801-5	1.7	133
436	Alzheimer's patients engage an alternative network during a memory task. *Annals of Neurology*, **2005**, 58, 870-9	9.4	132
435	Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type. *Neuroscience Letters*, **1984**, 44, 47-51	3.3	132
434	Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide. *Brain Research*, **1980**, 201, 249-53	3.7	131
433	Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. *NeuroImage*, **2004**, 23, 663-9	7.9	129
432	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. *Neurology*, **2018**, 91, e1295-e1306	6.5	129
431	Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. *Journal of Neurochemistry*, **1982**, 38, 1490-2	6	127
430	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. *Annals of Neurology*, **2000**, 48, 939-943	9.4	124
429	The isolation of calculation skills. *Journal of Neurology*, **1995**, 242, 78-81	5.5	124
428	Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **1987**, 1, 256-62	2.5	123
427	Alzheimer's pathology in primary progressive aphasia. *Neurobiology of Aging*, **2012**, 33, 744-52	5.6	121
426	Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. *Neuropathology and Applied Neurobiology*, **2004**, 30, 369-73	5.2	121
425	Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. *Archives of Neurology*, **2006**, 63, 1434-9		120
424	Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. *Archives of Neurology*, **2005**, 62, 1402-8		120
423	Vasopressin, oxytocin and neurophysins in the human brain and spinal cord. *Brain Research*, **1984**, 291, 111-7	3.7	119

422	Pick's disease is associated with mutations in the tau gene. *Annals of Neurology*, **2000**, 48, 859-867	9.4	116
421	Correlating familial Alzheimer's disease gene mutations with clinical phenotype. *Biomarkers in Medicine*, **2010**, 4, 99-112	2.3	113
420	Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. *Lancet, The*, **1999**, 353, 2125	40	113
419	Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. *Neuroscience*, **1988**, 25, 419-38	3.9	112
418	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. *NeuroImage*, **2007**, 35, 207-13	7.9	111
417	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. *Lancet Neurology, The*, **2016**, 15, 1326-1335	24.1	109
416	Young onset dementia. *Postgraduate Medical Journal*, **2004**, 80, 125-39	2	106
415	Brain biopsy in dementia. *Brain*, **2005**, 128, 2016-25	11.2	105
414	The genetic and pathological classification of familial frontotemporal dementia. *Archives of Neurology*, **2001**, 58, 1813-6		105
413	Regional distribution of neurotensin in human brain. *Journal of Neurochemistry*, **1982**, 38, 1777-80	6	105
412	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 191-196	5.6	104
411	Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. *Revue Neurologique*, **2013**, 169, 737-43	3	104
410	Word-finding difficulty: a clinical analysis of the progressive aphasias. *Brain*, **2008**, 131, 8-38	11.2	104
409	Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression. *Journal of Neurology*, **2008**, 255, 567-74	5.5	103
408	Primary progressive aphasia: a clinical approach. *Journal of Neurology*, **2018**, 265, 1474-1490	5.5	101
407	Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. *Archives of Neurology*, **2000**, 57, 220-4		98
406	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathologica*, **2014**, 127, 407-18	14.3	97
405	Distribution of cholecystokinin-like peptides in the human-brain. *Journal of Neurochemistry*, **1982**, 38, 1177-9	6	95

404	Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. *Journal of the Neurological Sciences*, **1980**, 48, 303-13	3.2	94
403	Huntington's disease phenocopies are clinically and genetically heterogeneous. *Movement Disorders*, **2008**, 23, 716-20	7	93
402	Syndromes of nonfluent primary progressive aphasia: a clinical and neurolinguistic analysis. *Neurology*, **2010**, 75, 603-10	6.5	90
401	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurology, The*, **2020**, 19, 145-156	24.1	90
400	Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates. *NeuroImage*, **2004**, 23, 574-81	7.9	89
399	A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. *Neurodegenerative Diseases*, **2007**, 4, 185-94	2.3	85
398	Profiles of white matter tract pathology in frontotemporal dementia. *Human Brain Mapping*, **2014**, 35, 4163-79	5.9	84
397	Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia. *Brain and Language*, **2013**, 127, 121-6	2.9	84
396	Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. *Neuroscience Letters* , **2003**, 336, 167-70	3.3	84
395	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. *Neuroscience Letters*, **1992**, 137, 221-4	3.3	84
394	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. *Human Molecular Genetics*, **2015**, 24, 5260-9	5.6	83
393	Topographical short-term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration. *Hippocampus*, **2010**, 20, 1154-69	3.5	83
392	Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. *Archives of Neurology*, **2005**, 62, 1410-5		82
391	Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease. *Brain Research*, **1980**, 198, 497-500	3.7	82
390	Assessing quality of life in dementia: Preliminary psychometric testing of the Quality of Life Assessment Schedule (QOLAS). *Neuropsychological Rehabilitation*, **2001**, 11, 219-243	3.1	77
389	White matter tract signatures of the progressive aphasias. *Neurobiology of Aging*, **2013**, 34, 1687-99	5.6	76
388	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. *Neuroscience Letters*, **2003**, 341, 177-80	3.3	76
387	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. *Brain*, **2011**, 134, 293-300	11.2	75

386	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. *Brain*, **2015**, 138, 3360-72	11.2	74
385	R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. *Alzheimer's and Dementia*, **2014**, 10, 602-608.e4	1.2	74
384	Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 20, 587-98	4.3	73
383	A new variant of prion disease. *Lancet, The*, **1996**, 347, 916-7	40	72
382	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. *Brain*, **2018**, 141, 3065-3080	11.2	72
381	Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. *Neuroscience Letters*, **1986**, 70, 154-9	3.3	71
380	Normal cortical concentration of cholecystokinin-like immunoreactivity with reduced choline acetyltransferase activity in senile dementia of Alzheimer type. *Life Sciences*, **1981**, 29, 405-10	6.8	71
379	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurology, The*, **2019**, 18, 1103-1111	24.1	68
378	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. *JAMA Neurology*, **2014**, 71, 1111-22	17.2	68
377	Apraxia in progressive nonfluent aphasia. *Journal of Neurology*, **2010**, 257, 569-74	5.5	66
376	Longitudinal patterns of regional change on volumetric MRI in frontotemporal lobar degeneration. *Dementia and Geriatric Cognitive Disorders*, **2004**, 17, 307-10	2.6	66
375	Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. *International Journal of Geriatric Psychiatry*, **2003**, 18, 67-72	3.9	66
374	Screening for mutations in the open reading frame and promoter of the beta-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val-->Ile. *Human Molecular Genetics*, **1992**, 1, 165-8	5.6	66
373	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. *Brain*, **2011**, 134, 2548-64	11.2	65
372	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). *Lancet Neurology, The*, **2016**, 15, 1317-1325	24.1	64
371	Dementia and Parkinson's disease--pathological and neurochemical considerations. *British Medical Bulletin*, **1986**, 42, 86-90	5.4	64
370	Extrahypothalamic vasopressin in human brain. *Brain Research*, **1981**, 214, 349-55	3.7	64
369	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 862-71	1.2	64

368	Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. *Neurobiology of Aging*, **2007**, 28, 20-8	5.6	63
367	Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. *Dementia and Geriatric Cognitive Disorders*, **2005**, 19, 338-44	2.6	63
366	Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. *American Journal of Medical Genetics Part A*, **1995**, 60, 1-6		63
365	Receptive prosody in nonfluent primary progressive aphasias. *Cortex*, **2012**, 48, 308-16	3.8	60
364	Familial dementia with swollen achromatic neurons and corticobasal inclusion bodies: a clinical and pathological study. *Journal of the Neurological Sciences*, **1996**, 135, 21-30	3.2	60
363	Monitoring cognitive changes: psychometric properties of six cognitive tests. *British Journal of Clinical Psychology*, **2004**, 43, 197-210	3.6	59
362	Prospective study of HTLV-I infection in an initially asymptomatic cohort. *Journal of Acquired Immune Deficiency Syndromes*, **1999**, 22, 92-100		59
361	Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. *Archives of Neurology*, **1990**, 47, 1318-23		59
360	Genetic analysis of inherited leukodystrophies: genotype-phenotype correlations in the CSF1R gene. *JAMA Neurology*, **2013**, 70, 875-882	17.2	58
359	Some workmen can blame their tools: artistic change in an individual with Alzheimer's disease. *Lancet, The*, **2001**, 357, 2129-33	40	58
358	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. *Alzheimer's Research and Therapy*, **2018**, 10, 32	9	57
357	Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. *Neuroscience Letters*, **1997**, 235, 5-8	3.3	57
356	Validation of next-generation sequencing technologies in genetic diagnosis of dementia. *Neurobiology of Aging*, **2014**, 35, 261-5	5.6	56
355	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. *Neurology*, **2013**, 81, 1425-33	6.5	56
354	Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. *Neurobiology of Aging*, **2012**, 33, 426.e13-21	5.6	55
353	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 7619-23	11.5	55
352	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. *Brain*, **2015**, 138, 1036-45	11.2	54
351	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. *Brain*, **2018**, 141, 1186-1200	11.2	54

350	Apolipoprotein e genotype modifies the phenotype of Alzheimer disease. *Archives of Neurology*, **2006**, 63, 155-6		54
349	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. *Neuroscience Letters*, **1996**, 214, 33-6	3.3	54
348	Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. *Neuroscience Letters*, **1994**, 172, 77-9	3.3	54
347	Dopamine D-1 and D-2 receptors in Huntington's disease. *European Journal of Pharmacology*, **1983**, 88, 223-9	5.3	54
346	Application of automated medial temporal lobe atrophy scale to Alzheimer disease. *Archives of Neurology*, **2007**, 64, 849-54		52
345	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. *Neurobiology of Aging*, **2013**, 34, 1996-2002	5.6	51
344	Transportin1: a marker of FTLD-FUS. *Acta Neuropathologica*, **2011**, 122, 591-600	14.3	50
343	ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. *American Journal of Medical Genetics Part A*, **1998**, 81, 117-21		49
342	Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. *Annals of the New York Academy of Sciences*, **1996**, 777, 226-32	6.5	49
341	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. *Brain*, **2016**, 139, 2766-2777	11.2	48
340	Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. *Archives of Neurology*, **2008**, 65, 506-13		48
339	The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. *Archives of Neurology*, **2004**, 61, 1743-8		48
338	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. *Lancet Neurology, The*, **2018**, 17, 123-132	24.1	47
337	The role of variation at APP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 28, 377-87	4.3	47
336	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 3140-3151	5.6	46
335	Genetic variability in CLU and its association with Alzheimer's disease. *PLoS ONE*, **2010**, 5, e9510	3.7	46
334	Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. *European Journal of Neurology*, **2000**, 7, 133-44	6	46
333	Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1274-8	5.5	45

332	Extensive and temporally ungraded retrograde amnesia in encephalitis associated with antibodies to voltage-gated potassium channels. *Archives of Neurology*, **2007**, 64, 404-10		45
331	Autonomic failure preceding dementia with Lewy bodies. *Journal of Neurology*, **2000**, 247, 229-31	5.5	45
330	Morphological overlap between corticobasal degeneration and Pick's disease: a clinicopathological report. *Movement Disorders*, **1995**, 10, 111-4	7	44
329	White matter hyperintensities are seen only in mutation carriers in the GENFI cohort. *NeuroImage: Clinical*, **2017**, 15, 171-180	5.3	43
328	Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. *Neurology*, **2016**, 87, 2050-2057	6.5	43
327	Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. *Neurodegenerative Diseases*, **2011**, 8, 149-52	2.3	43
326	Consent recommendations for research and international data sharing involving persons with dementia. *Alzheimers and Dementia*, **2018**, 14, 1334-1343	1.2	42
325	Quantitative magnetization transfer imaging in Alzheimer disease. *Radiology*, **2007**, 244, 832-7	20.5	42
324	Association between autoimmune thyroid disease and familial Alzheimer's disease. *Clinical Endocrinology*, **1991**, 35, 93-6	3.4	42
323	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. *EMBO Molecular Medicine*, **2018**, 10,	12	41
322	Delusions in frontotemporal lobar degeneration. *Journal of Neurology*, **2009**, 256, 600-7	5.5	40
321	Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. *American Journal of Medical Genetics Part A*, **1993**, 48, 129-30		40
320	Rates of hemispheric and lobar atrophy in the language variants of frontotemporal lobar degeneration. *Journal of Alzheimers Disease*, **2012**, 30, 407-11	4.3	39
319	Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 512-9	5.5	38
318	Acceleration of cortical thinning in familial Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 1765-73	5.6	38
317	Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. *Neuropsychologia*, **2008**, 46, 1732-7	3.2	38
316	Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. *Journal of Neurology*, **2006**, 253, 1147-53	5.5	38
315	Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. *Biochemical and Biophysical Research Communications*, **1994**, 201, 722-6	3.4	38

314	Prion protein immunocytochemistry helps to establish the true incidence of prion diseases. *Neuroscience Letters*, **1992**, 147, 67-71	3.3	37
313	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. *Brain*, **2019**, 142, 2082-2095	11.2	36
312	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2017**, 9, 85	9	36
311	Mapping the progression of progranulin-associated frontotemporal lobar degeneration. *Nature Clinical Practice Neurology*, **2008**, 4, 455-60		36
310	An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. *NeuroImage*, **2004**, 22, 134-43	7.9	36
309	Sporadic fatal insomnia: A case study. *Annals of Neurology*, **2000**, 48, 665-669	9.4	36
308	Confirmation that familial clustering and age of onset in late onset Alzheimer's disease are determined at the apolipoprotein E locus. *Neuroscience Letters*, **1994**, 174, 222-4	3.3	36
307	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. *Molecular Psychiatry*, **2020**,	15.1	36
306	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. *Annals of Neurology*, **2000**, 48, 939-43	9.4	36
305	Auditory hedonic phenotypes in dementia: A behavioural and neuroanatomical analysis. *Cortex*, **2015**, 67, 95-105	3.8	35
304	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. *PLoS ONE*, **2012**, 7, e43099	3.7	35
303	Alzheimer's disease families with amyloid precursor protein mutations. *Annals of the New York Academy of Sciences*, **1993**, 695, 198-202	6.5	35
302	Sequencing of exons 16 and 17 of the beta-amyloid precursor protein gene in 14 families with early onset Alzheimer's disease fails to reveal mutations in the beta-amyloid sequence. *Neuroscience Letters*, **1991**, 133, 1-2	3.3	35
301	No evidence for lateral asymmetry of neurotransmitters in post-mortem human brain. *Journal of Neurochemistry*, **1980**, 35, 743-5	6	35
300	Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion. *Science*, **1980**, 210, 1369-71	33.3	35
299	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. *Journal of Neurology*, **2015**, 262, 2722-30	5.5	34
298	Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal dementia. *Journal of Neurology*, **2015**, 262, 2635-42	5.5	34
297	Neuroanatomical profiles of personality change in frontotemporal lobar degeneration. *British Journal of Psychiatry*, **2011**, 198, 365-72	5.4	34

296	Molecular genetic characterisation of frontotemporal dementia on chromosome 3. *Dementia and Geriatric Cognitive Disorders*, **1999**, 10 Suppl 1, 93-101	2.6	34
295	Neurotensin in human brain: regional distribution and effects of neurological illness. *Brain Research* , **1985**, 347, 239-44	3.7	34
294	Alterations in brain opiate receptors in Parkinson's disease. *Brain Research*, **1979**, 173, 378-82	3.7	34
293	Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients. *Journal of the Neurological Sciences*, **1980**, 46, 385-92	3.2	34
292	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. *Molecular Psychiatry*, **2021**, 26, 614-628	15.1	34
291	Presymptomatic studies in genetic frontotemporal dementia. *Revue Neurologique*, **2013**, 169, 820-4	3	33
290	A volumetric magnetic resonance imaging study of the amygdala in frontotemporal lobar degeneration and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2005**, 20, 238-44	2.6	33
289	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 1197-1206	1.2	32
288	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. *Scientific Reports*, **2017**, 7, 1225	4.9	32
287	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). *Journal of Magnetic Resonance Imaging*, **2018**, 47, 131-140	5.6	32
286	Amnesia, cerebral atrophy, and autoimmunity. *Lancet, The*, **2003**, 361, 1266	40	32
285	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain*, **2017**, 140, 1784-1791	11.2	31
284	A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. *Neuropathology and Applied Neurobiology*, **2014**, 40, 502-13	5.2	31
283	Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. *Journal of Alzheimer's Disease*, **2013**, 35, 199-212	4.3	31
282	Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. *Journal of the Neurological Sciences*, **1997**, 149, 177-84	3.2	31
281	Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as 'cotton wool' plaques. *Neuropathology and Applied Neurobiology*, **2001**, 27, 189-96	5.2	31
280	Selective sparing of verb naming in a case of severe Alzheimer's disease. *Cortex*, **1999**, 35, 443-50	3.8	31
279	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1427-1437	1.2	31

278	Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. *Scientific Reports*, **2019**, 9, 4743	4.9	30
277	The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1405-7	5.5	30
276	The quantitative assessment of apraxic deficits in Alzheimer's disease. *Cortex*, **2007**, 43, 976-86	3.8	30
275	Insertions in the prion protein gene in atypical dementias. *Experimental Neurology*, **1991**, 112, 240-2	5.7	30
274	Benzodiazepine receptors: the effect of GABA on their characteristics in human brain and their alteration in Huntington's disease. *Brain Research*, **1980**, 199, 79-88	3.7	30
273	The regional distribution and chromatographic behaviour of somatostatin in human brain. *Neuroscience Letters*, **1981**, 22, 319-324	3.3	30
272	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 245.e9-245.e12	5.6	30
271	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1025-1036	5.3	29
270	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. *Neurobiology of Aging*, **2009**, 30, 656-65	5.6	29
269	Beta A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease. *Neuroscience Letters*, **1993**, 149, 137-40	3.3	29
268	Ornithine aminotransferase in Huntington's disease. *Brain Research*, **1982**, 231, 466-71	3.7	29
267	Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease. *Brain Research*, **1982**, 253, 341-3	3.7	29
266	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. *Alzheimer's and Dementia*, **2018**, 14, 43-53	1.2	28
265	Alzheimer's disease in the 100 years since Alzheimer's death. *Brain*, **2015**, 138, 3816-21	11.2	27
264	Amaurosis fugax in young people. *British Journal of Ophthalmology*, **1992**, 76, 660-2	5.5	27
263	Evidence for allelic heterogeneity in familial early-onset Alzheimer's disease. *British Journal of Psychiatry*, **1991**, 158, 471-4	5.4	27
262	Functional cognitive disorder: dementia's blind spot. *Brain*, **2020**, 143, 2895-2903	11.2	27
261	Positron emission tomography in familial Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **1995**, 9, 17-20	2.5	26

260	Regional distribution of pro-opiomelanocortin-derived peptides in the human brain. *Neuroendocrinology*, **1984**, 38, 45-50	5.6	26
259	A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. *Journal of Neurology*, **2011**, 258, 1494-6	5.5	25
258	Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. *Archives of Neurology*, **2005**, 62, 1097-101		25
257	The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. *Journal of Neurology*, **2004**, 251, 184-8	5.5	25
256	"-but who is that on the other side of you?" Extracampine hallucinations revisited. *Lancet, The*, **2002** , 360, 2064-6	40	25
255	Dementia and driving: European national guidelines. EFNS Scientist Panel on Dementia. *European Journal of Neurology*, **2000**, 7, 745	6	25
254	Hereditary vascular dementia linked to notch 3 mutations. CADASIL in British families. *Annals of the New York Academy of Sciences*, **2000**, 903, 293-8	6.5	25
253	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. *Neuroscience Letters*, **1999**, 260, 193-5	3.3	25
252	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
251	Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. *Neurocase*, **2018**, 24, 166-174	0.8	24
250	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 1016-23	5.5	24
249	Neologistic jargon aphasia and agraphia in primary progressive aphasia. *Journal of the Neurological Sciences*, **2009**, 277, 155-9	3.2	24
248	CANDID--Counselling and Diagnosis in Dementia: a national telemedicine service supporting the care of younger patients with dementia. *International Journal of Geriatric Psychiatry*, **1998**, 13, 381-8	3.9	24
247	the mini mental state examination. *Practical Neurology*, **2005**, 5, 298-303	2.4	24
246	Clinical features of sporadic and familial Alzheimer's disease. *Experimental Neurology*, **1996**, 5, 393-7		24
245	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. *Brain*, **2019**, 142, 1108-1120	11.2	23
244	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology*, **2015**, 85, 790-8	6.5	23
243	The Dementias Platform UK (DPUK) Data Portal. *European Journal of Epidemiology*, **2020**, 35, 601-611	12.1	23

242	Provisional clinical and neuroradiological criteria for the diagnosis of Pick's disease. *European Journal of Neurology*, **1998**, 5, 519-520	6	23
241	Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. *Neuroradiology*, **2006**, 48, 428-33	3.2	23
240	Test-retest reliability, practice effects and reliable change indices for the recognition memory test. *British Journal of Clinical Psychology*, **2003**, 42, 407-25	3.6	23
239	Clinical and neuroimaging features of familial Alzheimer's disease. *Annals of the New York Academy of Sciences*, **1996**, 777, 49-56	6.5	23
238	Evidence for multiple muscarinic receptor subtypes in human brain. *Journal of Neurochemistry*, **1984**, 43, 299-302	6	23
237	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. *Brain*, **2019**, 142, 1429-1440	11.2	22
236	Increased hippocampal atrophy rates in AD over 6 months using serial MR imaging. *Neurobiology of Aging*, **2008**, 29, 1199-203	5.6	22
235	Cognitive profile in dementia associated with vitamin B12 deficiency due to pernicious anaemia. *Journal of Neurology*, **1999**, 246, 317-9	5.5	22
234	Acquired Brown's syndrome: an unusual cause. *British Journal of Ophthalmology*, **1985**, 69, 791-4	5.5	22
233	Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. *International Journal of Geriatric Psychiatry*, **2021**, 36, 1597-1639	3.9	22
232	A novel technique for the quantitative assessment of apraxic deficits: application to individuals with mild cognitive impairment. *Journal of Neuropsychology*, **2007**, 1, 237-57	2.6	21
231	A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. *Alzheimer's Research and Therapy*, **2018**, 10, 44	9	20
230	Toward common mechanisms for risk factors in Alzheimer's syndrome. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 571-578	6	20
229	Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations. *Neurodegenerative Diseases*, **2004**, 1, 225-30	2.3	20
228	Autopsy-confirmed familial early-onset Alzheimer disease caused by the I153V presenilin 1 mutation. *Archives of Neurology*, **2001**, 58, 953-8		20
227	The distribution and characterisation of thyrotrophin releasing hormone (TRH) in the human brain. *Neuropeptides*, **1981**, 2, 115-122	3.3	20
226	Neuropeptides in degenerative disease of the central nervous system. *Trends in Neurosciences*, **1982**, 5, 399-401	13.3	20
225	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. *Journal of Alzheimer's Disease*, **2016**, 54, 1297-1302	4.3	20

224	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. *Alzheimer's and Dementia*, **2020**, 16, 501-511	1.2	20
223	Short TE quantitative proton magnetic resonance spectroscopy in variant Creutzfeldt-Jakob disease. *European Radiology*, **2006**, 16, 1692-8	8	19
222	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. *Movement Disorders*, **2003**, 18, 955-8	7	19
221	Apolipoprotein E genotyping in Alzheimer's disease. *Lancet, The*, **1996**, 347, 1775-1776	40	19
220	Central alveolar hypoventilation associated with paraneoplastic brain-stem encephalitis and anti-Hu antibodies. *Journal of Neurology*, **1994**, 241, 561-6	5.5	19
219	Brain muscarinic receptors in Alzheimer's and Parkinson's diseases. *Lancet, The*, **1989**, 2, 1279	40	19
218	Seizures as an early symptom of autosomal dominant Alzheimer's disease. *Neurobiology of Aging*, **2019**, 76, 18-23	5.6	19
217	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. *Molecular Psychiatry*, **2020**, 25, 3399-3412	15.1	19
216	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. *NeuroImage*, **2019**, 189, 645-654	7.9	18
215	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. *American Journal of Medical Genetics Part A*, **2004**, 125B, 79-82		18
214	Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **1998**, 12, 208-10	2.5	18
213	Neuropsychological profiles of familial Alzheimer's disease associated with mutations in the presenilin 1 and amyloid precursor protein genes. *Journal of Neurology*, **2001**, 248, 45-50	5.5	17
212	EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. First of two parts. *European Journal of Neurology*, **2001**, 8, 299-314	6	17
211	Distinguishable effects of presenilin-1 and APP717 mutations on amyloid plaque deposition. *Neurobiology of Aging*, **2001**, 22, 367-76	5.6	17
210	Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. Mutations in brief no. 223. Online. *Human Mutation*, **1999**, 13, 256	4.7	17
209	Sciatic nerve damage due to toilet seat entrapment: another Saturday night palsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **1989**, 52, 1113-5	5.5	17
208	Automated measurement of hippocampal atrophy using fluid-registered serial MRI in AD and controls. *Journal of Computer Assisted Tomography*, **2007**, 31, 581-7	2.2	16
207	Dementia with Lewy bodies studied with positron emission tomography. *Archives of Neurology*, **2001**, 58, 505-8		16

206	Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. *Neurology*, **2002**, 58, 838	6.5	16
205	Thalamic degeneration with negative prion protein immunostaining. *Journal of Neurology*, **2000**, 247, 48-51	5.5	16
204	A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. *Experimental Neurology*, **1996**, 5, 35-41		16
203	Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. *Lancet, The*, **1989**, 2, 743	40	16
202	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. *Brain Stimulation*, **2020**, 13, 1031-1039	5.1	15
201	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2011**, 156B, 764-71	3.5	15
200	Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation. *Dementia and Geriatric Cognitive Disorders*, **2009**, 27, 182-6	2.6	15
199	Shunt responsive progressive supranuclear palsy?. *Movement Disorders*, **2007**, 22, 902-3	7	15
198	Artistic changes in Alzheimer's disease. *International Review of Neurobiology*, **2006**, 74, 147-61	4.4	15
197	Dementia and driving: Results of a semi-realistic simulator study. *International Journal of Geriatric Psychiatry*, **1995**, 10, 859-864	3.9	15
196	Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia?. *Lancet, The*, **2015**, 386, 1008-10	40	14
195	A novel A781V mutation in the CSF1R gene causes hereditary diffuse leucoencephalopathy with axonal spheroids. *Journal of the Neurological Sciences*, **2013**, 332, 141-4	3.2	14
194	The uncertain nosology of Hashimoto encephalopathy. *Archives of Neurology*, **2003**, 60, 1812; author reply 1812		14
193	A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease. *Neurobiology of Aging*, **1987**, 8, 487-94	5.6	14
192	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. *JAMA Network Open*, **2021**, 4, e2030194	10.4	14
191	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2015**, 1, 440-446	5.2	13
190	Cerebral microbleeds in familial Alzheimer's disease. *Brain*, **2012**, 135, e201; author reply e202	11.2	13
189	Differential diagnosis of frontotemporal dementia: Pick's disease. *Dementia and Geriatric Cognitive Disorders*, **1999**, 10 Suppl 1, 43-5	2.6	13

188	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. *Brain*, **2021**, 144, 2176-2185	11.2	13
187	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. *NeuroImage: Clinical*, **2019**, 24, 102077	5.3	13
186	Abnormal laughter-like vocalisations replacing speech in primary progressive aphasia. *Journal of the Neurological Sciences*, **2009**, 284, 120-3	3.2	12
185	Education and training of European neurologists in dementia. *European Journal of Neurology*, **2007**, 14, 505-9	6	12
184	The Alien Limb. *Practical Neurology*, **2004**, 4, 44-45	2.4	12
183	Biological markers in mental disorders: post-mortem studies. *Journal of Psychiatric Research*, **1984**, 18, 457-65	5.2	12
182	Post-mortem neurochemical changes in Alzheimer's disease compared with normal ageing. *Canadian Journal of Neurological Sciences*, **1986**, 13, 499-502	1	12
181	Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 103-107	6	11
180	Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion. *Alzheimer's Research and Therapy*, **2012**, 4, 42	9	11
179	Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease. *International Journal of Geriatric Psychiatry*, **2010**, 25, 1119-26	3.9	11
178	National survey to assess current practices in the diagnosis and management of young people with dementia. *International Journal of Geriatric Psychiatry*, **2002**, 17, 124-7	3.9	11
177	A case of sporadic Pick disease with onset at 27 years. *Archives of Neurology*, **1999**, 56, 1289-91		11
176	Apolipoprotein E alleles but neither apolipoprotein B nor apolipoprotein AI/CIII alleles are associated with late onset, familial Alzheimer's disease. *Neuroscience Letters*, **1995**, 188, 202-4	3.3	11
175	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. *Annals of Neurology*, **2020**, 88, 113-122	9.4	11
174	A cognitive chameleon: lessons from a novel MAPT mutation case. *Neurocase*, **2014**, 20, 684-94	0.8	10
173	A novel presenilin 1 deletion (p.L166del) associated with early onset familial Alzheimer's disease. *European Journal of Neurology*, **2007**, 14, 829-31	6	10
172	Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes. *Annals of Neurology*, **2006**, 60, 616; author reply 617	9.4	10
171	Alzheimer's disease. Unravelling the disease process. *Lancet, The*, **2001**, 358 Suppl, S1	40	10

170	Genetic characterization of a familial non-specific dementia originating in Jutland, Denmark. *Journal of the Neurological Sciences*, **1993**, 114, 138-43	3.2	10
169	Management of neurological disorders: dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **1994**, 57, 1451-6	5.5	10
168	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. *NeuroImage*, **2019**, 188, 282-290	7.9	10
167	Binary reversals in primary progressive aphasia. *Cortex*, **2016**, 82, 287-289	3.8	9
166	Donepezil enhances understanding of degraded speech in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2017**, 4, 835-840	5.3	9
165	Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid β peptides. *Expert Opinion on Therapeutic Patents*, **1997**, 7, 1115-1127	6.8	9
164	Symptoms of memory loss as predictors of cognitive impairment?: the use and reliability of memory ratings in a clinic population. *Alzheimer Disease and Associated Disorders*, **2007**, 21, 101-6	2.5	9
163	Clinical-anatomical correlation in a selective phonemic speech production impairment. *Journal of the Neurological Sciences*, **2004**, 219, 23-9	3.2	9
162	TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMN. *Neurology*, **2019**, 92, e951-e956	6.5	9
161	Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1411-2	5.5	8
160	Olfactory impairment in posterior cortical atrophy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 588-90	5.5	8
159	HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. *BMC Medical Genetics*, **2009**, 10, 90	2.1	8
158	Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. *Reviews in the Neurosciences*, **1996**, 7, 21-8	4.7	8
157	Dementia associated with haemochromatosis: a report of two cases. *European Journal of Neurology*, **1997**, 4, 318-322	6	8
156	Zoster paresis with Horner's syndrome. *Journal of Neurology*, **2003**, 250, 1492-3	5.5	8
155	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. *Alzheimer's and Dementia*, **2021**, 17, 500-514	1.2	8
154	CHCHD10 Pro34Ser is not a highly penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. *Brain*, **2016**, 139, e9	11.2	7
153	Supporting clinical research in the NHS in England: the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. *Alzheimer's Research and Therapy*, **2012**, 4, 23	9	7

152	The Cystatin-C gene is not linked to early onset familial Alzheimer's disease. *Neuroscience Letters*, **1993**, 154, 81-3	3.3	7
151	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. *Cortex*, **2020**, 133, 384-398	3.8	7
150	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. *Alzheimer's Research and Therapy*, **2020**, 12, 112	9	7
149	Pick's disease is associated with mutations in the tau gene **2000**, 48, 859		7
148	Pick's Disease156-164		7
147	Pure progressive amnesia and the APPV717G mutation. *Alzheimer Disease and Associated Disorders*, **2009**, 23, 410-4	2.5	6
146	Knight's move thinking? Mild cognitive impairment in a chess player. *Neurocase*, **2005**, 11, 26-31	0.8	6
145	Snouting, Pouting and Rooting. *Practical Neurology*, **2001**, 1, 119-121	2.4	6
144	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. *Movement Disorders*, **2001**, 16, 382-395	7	6
143	Modelling the occurrence and pathology of Alzheimer's disease. *Neurobiology of Aging*, **1989**, 10, 429-31; discussion 446-8	5.6	6
142	Post-mortem neurochemistry of human brain. *Progress in Brain Research*, **1986**, 65, 167-75	2.9	6
141	Quantitative distribution of neurohypophysial hormones in human brain and spinal cord. *Progress in Brain Research*, **1983**, 60, 123-8	2.9	6
140	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. *Brain Communications*, **2020**, 2,	4.5	6
139	Differential early subcortical involvement in genetic FTD within the GENFI cohort. *NeuroImage: Clinical*, **2021**, 30, 102646	5.3	6
138	Compulsive versifying after treatment of transient epileptic amnesia. *Neurocase*, **2015**, 21, 548-53	0.8	5
137	Seeing what alzheimer saw-with magnetic resonance microscopy. *Nature Medicine*, **2000**, 6, 20-1	50.5	5
136	Relationships between beta-amyloid (A beta) deposits and blood vessels in patients with sporadic and familial Alzheimer's disease. *Neuroscience Letters*, **1996**, 207, 171-4	3.3	5
135	Screening for the APP codon 670/671 mutations in Alzheimer's disease. *Neuroscience Letters*, **1993**, 154, 161-2	3.3	5

134	A novel prion protein variant in a patient with semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 890-892	5.5	4
133	Dementia and Cognitive Impairment **2016**, 289-336		4
132	Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis. *Movement Disorders*, **1999**, 14, 523-5	7	4
131	Alzheimer's disease: the entity and its cause. *Biochemical Society Transactions*, **1989**, 17, 67-9	5.1	4
130	TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S DISEASE. *Lancet, The*, **1987**, 329, 444-445	40	4
129	Longitudinal (F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 106-108	5.5	4
128	The palmomental reflex: stop scratching around!. *Practical Neurology*, **2016**, 16, 500-501	2.4	4
127	Cognitive Impairment and Dementia245-288		3
126	O4-05-08 Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. *Neurobiology of Aging*, **2004**, 25, S84-S85	5.6	3
125	Bilateral thalamic pain secondary to bilateral thalamic infarcts relieved by a further unilateral ischaemic episode. *European Journal of Neurology*, **1999**, 6, 717-9	6	3
124	Medial medullary syndrome associated with patent foramen ovale in a weightlifter. *European Neurology*, **1996**, 36, 391	2.1	3
123	Alzheimer's disease. *Postgraduate Medical Journal*, **1992**, 68, 528-32	2	3
122	Molecular genetics of Alzheimer's disease. *Biochemical Society Transactions*, **1989**, 17, 75-6	5.1	3
121	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. *Biological Psychiatry*, **2021**, 89, 825-833	7.9	3
120	Aphasic Binary Reversals in Patients With Neurological Disease as a Barrier to Clinical Decision Making. *JAMA Neurology*, **2019**, 76, 234-235	17.2	3
119	The undiscovered syndrome: Macdonald Critchley's case of semantic dementia. *Neurocase*, **2015**, 21, 408-12	0.8	2
118	Comparison of digital platforms for participant recruitment in dementia research: Lessons and future directions from a global collaborative. *Alzheimer's and Dementia*, **2020**, 16, e046401	1.2	2
117	The Language of Neurology **2016**, 97-131		2

116	[P1596]: DEVELOPING STANDARDS FOR RESEARCH REGISTERS: APPLYING LEARNING FROM THE U.K.'s NATIONAL JOIN DEMENTIA RESEARCH SERVICE **2017**, 13, P524-P524		2
115	F2-03-04: Genetic risk factors for posterior cortical atrophy **2015**, 11, P168-P169		2
114	Suspected early dementia. *BMJ, The*, **2011**, 343, d5568	5.9	2
113	Does registration of serial MRI improve diagnosis of dementia?. *Neuroradiology*, **2010**, 52, 987-95	3.2	2
112	Observations on the human rejection behaviour syndrome: Denny-Brown revisited. *Movement Disorders*, **2004**, 19, 860-862	7	2
111	A 38-year-old man with a 9 month history of neurological and cognitive impairment. *Lancet Neurology, The*, **2003**, 2, 189-94	24.1	2
110	Early diagnosis of dementia. *Journal of Neurology*, **1999**, 246, 4-5	5.5	2
109	Exclusion mapping in familial non-specific dementia. *Dementia and Geriatric Cognitive Disorders*, **1993**, 4, 163-6	2.6	2
108	Stability of pro-opiocortin-related peptides in post-mortem mouse brain tissue. *Neuroendocrinology* , **1982**, 35, 336-41	5.6	2
107	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. *Alzheimer's and Dementia*, **2021**,	1.2	2
106	Inspired by chance: valuing patients' informal contributions to research. *BMJ, The*, **2020**, 371, m4478	5.9	2
105	Early Implementation and Evaluation of StepUp for Dementia Research: An Australia-Wide Dementia Research Participation and Public Engagement Platform. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	2
104	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. *Alzheimer's Research and Therapy*, **2021**, 13, 127	9	2
103	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimer's Disease **2016**, 12, P231-P231		2
102	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. *Movement Disorders*, **2021**, 36, 632-641	7	2
101	Suspecting dementia: canaries, chameleons and zebras. *Practical Neurology*, **2021**,	2.4	2
100	Disease-related cortical thinning in presymptomatic granulin mutation carriers. *NeuroImage: Clinical* , **2021**, 29, 102540	5.3	2
99	The cognitive footprint of medication: A review of cognitive assessments in clinical trials. *Journal of Clinical Pharmacy and Therapeutics*, **2020**, 45, 874-880	2.2	1

98	How dementia and neurodegenerative disease clinical research networks have enhanced research delivery in England. *Clinical Investigation*, **2014**, 4, 687-691		1
97	Association between human herpesvirus infections and dementia or mild cognitive impairment: a systematic review protocol. *BMJ Open*, **2017**, 7, e016522	3	1
96	[P2‐64]: ENCOURAGING PUBLIC PARTICIPATION IN DEMENTIA RESEARCH: ANALYSIS OF TAKE-UP AND COSTS FOLLOWING MAIL OUT TO 10,000 PATIENTS WITHIN GENERAL PRACTICE **2017**, 13, P861-P861		1
95	The Language of Neurology: Symptoms, Signs and Basic Investigations75-107		1
94	The cultural context of visual hallucinations. *Postgraduate Medical Journal*, **2008**, 84, 103-5	2	1
93	Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **1995**, 59, 343	5.5	1
92	Recent advances in the understanding of dementia. *Postgraduate Medical Journal*, **1988**, 64, 99-106	2	1
91	Cholecystokinin content in the basal ganglia in Huntington's disease. The expression of cholecystokinin immunoreactivity in striatal grafts to ibotenic acid-lesioned rat striatum. *Annals of the New York Academy of Sciences*, **1985**, 448, 488-94	6.5	1
90	The Active Brains Digital Intervention to Reduce Cognitive Decline in Older Adults: Protocol for a Feasibility Randomized Controlled Trial. *JMIR Research Protocols*, **2020**, 9, e18929	2	1
89	Lessons in familial Alzheimer‐s disease **2001**, 259-265		1
88			
87	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. *Scientific Reports*, **2020**, 10, 12184	4.9	1
86	Teaching NeuroImages: Nonfluent variant primary progressive aphasia: A distinctive clinico-anatomical syndrome. *Neurology*, **2016**, 87, e283	6.5	1
85	TD-P-004: Harnessing Consumer Technologies and Clinical Data to Improve Recruitment to Clinical Studies: a Review of the First 12 Months of the Join Dementia Research Service in the United Kingdom **2016**, 12, P153-P153		1
84	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12185	5.2	1
83	Reply: Functional cognitive disorder: dementia's blind spot. *Brain*, **2021**, 144, e73	11.2	1
82	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.. *Alzheimer's Research and Therapy*, **2022**, 14, 10	9	0
81	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. *Neurobiology of Aging*, **2021**, 103, 137.e1-137.e5	5.6	0

80	The Dementia UK Ecosystem: a call to action. *Lancet Neurology, The*, **2021**, 20, 699-700	24.1	0
79	Plasma phospho-tau in familial Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e042921	1.2	
78	FTS2-01-05: From the who Research Priorities and Research Portfolio Analysis to the Identification of Research Gaps to Reduce the Global Burden of Dementia **2016**, 12, P220-P220		
77	IC-P-175: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE **2014**, 10, P97-P98		
76	F1-03-01: DIAN OVERVIEW AND COHORT CHARACTERISTICS **2014**, 10, P126-P127		
75	O1-07-02: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE **2014**, 10, P141-P142		
74	IC-P-106: LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE **2014**, 10, P59-P60		
73	IC-P-054: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study **2015**, 11, P42-P42		
72	IC-P-117: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes **2015**, 11, P80-P81		
71	P1-191: Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias **2015**, 11, P421-P422		
70	P1-211: Genetic influences on amyloid angiopathy and white matter pathology in familial Alzheimer's disease: A comparison of app and PSEN1 mutations **2015**, 11, P431-P431		
69	P2-120: Dementia and music: fMRI signatures of molecular nexopathies **2015**, 11, P528-P528		
68	IC-O102: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent? **2013**, 9, P3-P4		
67	[P2441]: PATHOLOGICAL CORRELATES OF WHITE MATTER HYPERINTENSITIES ON CADAVERIC MRI IN PROGRANULIN-ASSOCIATED FRONTOTEMPORAL DEMENTIA **2017**, 13, P805-P805		
66	[P2477]: DONEPEZIL MODULATES PERCEPTUAL LEARNING IN ALZHEIMER's DISEASE **2017**, 13, P823-P823		
65	[P3208]: EFFECT OF DONEPEZIL ON TRANSCRANIAL MAGNETIC STIMULATION PARAMETERS IN ALZHEIMER's DISEASE **2017**, 13, P1015-P1016		
64	[P3358]: DEMENTIAS PORTFOLIO DEVELOPMENT ACTIVITIES: UNITING AND SUPPORTING THE RESEARCH COMMUNITY TO INCREASE RESEARCH INCOME **2017**, 13, P1192-P1192		
63	[IC-P-150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING **2017**, 13, P113-P113		

62 [P1035]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT **2017**, 13, P384-P385

61 [O1002]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING **2017**, 13, P185-P186

60 [F4004]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE **2017**, 13, P1211

59 [O4004]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY **2017**, 13, P1230-P1231

58 [P4570]: A DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER CLINICAL TRIAL OF DONEPEZIL IN POSTERIOR CORTICAL ATROPHY DUE TO UNDERLYING ALZHEIMER's DISEASE: DONIPAD STUDY **2017**, 13, P1571

57 O3-14-01: Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis **2015**, 11, P254-P254

56 IC-P-049: Detailed structural analysis of the hypothalamus in behavioral variant frontotemporal dementia **2015**, 11, P39-P40

55 O2-01-06: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease **2015**, 11, P174-P174

54 O2-10-04: Detailed structural analysis of the hypothalamus in behavioral variant frontotemporal dementia **2015**, 11, P198-P199

53 IC-P-050: Volumetry of the cerebellum and its subregions in genetic frontotemporal dementia **2015** , 11, P40-P40

52 IC-P-118: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease **2015**, 11, P81-P81

51 P2-127: Volumetry of the cerebellum and its subregions in genetic frontotemporal dementia **2015**, 11, P532-P532

50 O2-01-01: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study **2015**, 11, P171-P171

49 O2-01-05: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes **2015**, 11, P173-P174

48 COMPULSIVE VERSIFYING IN TRANSIENT EPILEPTIC AMNESIA. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, e4.193-e4 5.5

47 O1-05-01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features **2012**, 8, P92-P93

46 Neurology in motion. *Clinical Medicine*, **2013**, 13, 443 1.9

45 LONGITUDINAL RESEARCH INTO ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA AND OTHER DEMENTIAS. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, e2.187-e2 5.5

44	Microsatellite D21S210 (GT-12) allele frequencies in sporadic Alzheimer's disease. *Acta Neurologica Scandinavica*, **1995**, 91, 145-8	3.8
43	Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology. *Annals of Neurology*, **2004**, 56, 604; author reply 604	9.4
42	Survival in Alzheimer Disease: Reply. *Archives of Neurology*, **2005**, 62, 689	
41	MRI findings in an individual at risk for familial Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **1993**, 4, 120	2.6
40	Solitary intracranial plasmacytoma presenting as lateral rectus palsy: Report of a case and review of neuro-ophthalmic manifestations of plasmacytoma. *Neuro-Ophthalmology*, **1990**, 10, 109-113	0.9
39	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort.. *Cortex*, **2022**, 150, 12-28	3.8
38	A national open-access research registry to improve recruitment to clinical studies.. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2021**, 7, e12221	6
37	A cross-sectional study of memory and executive functions in patients with sporadic inclusion body myositis. *Muscle and Nerve*, **2021**, 65, 105	3.4
36	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. *Journal of Cerebral Blood Flow and Metabolism*, **2005**, 25, S591-S591	7.3
35	One hundred years of shared interest. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 225-226	3.5
34	FTS3-01-04: Setting the Agenda: Prevention Studies for Vascular Contributions to Dementia **2016**, 12, P277-P277	
33	P1-025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI) **2016**, 12, P409-P411	
32	IC-P-142: A Longitudinal Morphometric Study of Familial Alzheimer's Disease: Results from Dian **2016**, 12, P105-P106	
31	O1-07-01: A Longitudinal Morphometric Study of Familial Alzheimer's Disease: Results From DIAN **2016**, 12, P187-P189	
30	F5-02-02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian **2016**, 12, P368-P369	
29	F5-02-03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease **2016**, 12, P369-P369	
28	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network **2016**, 12, P378-P379	
27	Better together for better dementia research and care. *Lancet Psychiatry,the*, **2016**, 3, 503-4	23.3

8 The Medical School and the Institute of Neurology418-438

7 The Rise of Academic Neurology at Queen Square 1962–1997439-476

6 Never, Never, Ever Change and Integration 1962–1997477-521

5 Medical and Surgical Appointees to the National Hospitals and/or Institute of Neurology 1859–1997522-529

4 Dates of Appointment of Senior Administrative Positions at the National Hospital/Institute of Neurology 1859–1997530-531

3 Physicians National Hospital 1860–1997532-535

2 IN 2014 CAN WE PREVENT DEMENTIA?. *Transactions of the Medical Society of London*, **2013**, 130, 59-63

1 Psychiatric symptoms in patients with focal cortical degeneration. *Behavioural Neurology*, **1994**, 7, 153-83